Published in Physician Law Weekly, September 27th, 2006
According to a study from Finland, "Retroanandamide and its 10 analogues were synthesized and evaluated for the cannabinoid receptor activation by a [35S]GTP gamma S binding assay using rat cerebellar membranes, and Chinese hamster ovary cell membranes expressing human CB2 receptors. The primary goal of the study was to develop cannabinoid receptor agonists having improved enzymatic stability compared to endogenous N-arachidonoyl ethanolamide (AEA)."
"Furthermore, by reversing the amide bond of AEA, the formation of arachidonic acid would be prevented,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly